Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple risk score catch a dangerous heart condition before it strikes?

NCT ID NCT05898165

Diagnosis Sponsor: University of Leeds Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether a new risk score can help find people who have atrial fibrillation (an irregular heartbeat) but don't know it yet. About 1,955 adults at higher risk will use a remote ECG monitor at home. The goal is to see if the risk score correctly identifies who is more likely to have AF, so they can get treated earlier and avoid strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
risk score algorithm and remote ECG monitoring
What this could lead to
If successful, this approach could help doctors find undiagnosed atrial fibrillation earlier, potentially preventing strokes.
What could go wrong
This is a pilot study, so it is small and early. The risk score may not work as well in real-world settings, and remote monitoring might miss some cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,955 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged \>30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings. Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping. Patient with new AF detected will be managed by their primary care clinicians.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age at enrolment ≥30 years * Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3 Exclusion Criteria: * Known diagnosis of AF * On anticoagulation therapy * On the palliative care register * Unable to give written informed consent for participation in the study * Unable to adhere to the study requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation cardiovascular disorder heart disorder stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Cardiovascular diseases Heart diseases

Contacts and locations

Locations

  • University of Leeds

    Leeds, West Yorkshire, LS2 9JT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.